Patient-reported Impact of ≥75% Increase in Good Days/Month on Migraine Symptoms, Quality of Life, and Brain Fog: Real-world Study of Adults With Chronic Migraine Treated With Eptinezumab (P12-12.010)
This post-hoc analysis examined the impact of ≥75% increase in self-reported good days/month on migraine symptoms, quality of life (QoL), and brain fog in patients treated with eptinezumab from REVIEW, a real-world evidence study.
Authors
- Ryan M. Smith (ORCID: https://orcid.org/0000-0001-9006-4347)
- Charles E. Argoff (ORCID: https://orcid.org/0000-0002-4961-8069)
- Fawad Khan (ORCID: https://orcid.org/0000-0003-0486-5004)
- Susanne F. Awad (ORCID: https://orcid.org/0000-0002-5060-7404)
- Foram Patel
- Seema Soni-Brahmbhatt (ORCID: https://orcid.org/0000-0002-4714-6010)
- Sharon R. Grossman (ORCID: https://orcid.org/0000-0001-6422-1134)
- Steven Herzog
Institutions
- Lundbeck (Denmark) (DK)
- Saint Luke's Health System (US)
- Neurosciences Institute (US)
- Ochsner Medical Center (US)
- Lundbeck (Germany) (DE)
- Texas Neurology (US)
- Albany Medical Center Hospital (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211355
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00